Connor Iapoce

Elaine M. Apperson discusses treating diabetes in a pediatric population, including diabetes burnout, the effects of food deserts, and the consequences of COVID-19 on treatment.

Data show event rates varied two-fold across regions, with risk reduction of T2D and CKD events across geographic regions without heterogeneity.

Part 2 of a Q&A with Elena Christofides, MD highlighting important discussions surrounding ADA 2021, including semaglutide and obesity treatments as they relate to T2D.

In part 1 of a Q&A, Elena Christofides, MD highlights important discussions surrounding ADA 2021, including cardiometabolic medicine and risk factors for T1D.

Data show similar family impact and distress scores at baseline and 3-months, highlighting continued impact of COVID-19 on T1D population.

Matthew Budoff, MD highlights his own preferred methods of treatment and what might need to be done to help doctors and patients through the process.

Data show a 38% reduction in T2D incidence with dapagliflozin compared to placebo in patients with CKD.

Data show 66% of healthcare professionals reported greater confidence in prescribing SGLT2i, while 55% reported greater confidence in prescribing GLP-1.

Data show 37.5% of patients in study were found to have moderate to severe DD, with an average score of ≥2.

Data show consistent benefit of finerenone on kidney and CV outcomes in patients with CKD and T2D, regardless of SGLT-2i use.

Over half of patients attained target A1C <7%. while a third of patients attained target A1C of <8%.

Data show no evidence of increased risk of adverse events in patients aged ≥80 years, compared to patients aged 70 - 79 years.

New data presented at ADA 2021 show GLP-1RA treatment is budget neutral in comparison to SoC, citing lower inpatient and outpatient cost.

New data show liraglutide reduced visceral, ectopic fat, with greater effects seen compared to weight loss.

Data show pain scores were significantly lower in ibuprofen treatment group compared to acetaminophen.

Study data show AF developed in 3745 patients, at an incidence rate of 15.3 per 1000 person-years.

Patient-reported scores showed no overall differences across 3- and 12- month follow-up.

Investigators considered myocarditis favorable to COVID-19 infection, with resolution of symptoms in all patients.

Both the Mediterranean Diet and the Specific Carbohydrate diet achieved nearly 50% symptomatic remission in patients with IBD.

The skin graft is produced from 2 types of human skin cells, keratinocytes and dermal fibroblasts.

Data show higher risk for incident cancer observed with PCE of <7.2%, while higher PCE led to increased risk of incident CVD.

Data show variations in the type, effectiveness, and implementation of QI strategies for patients with CVD.

Opioid prescription decreased substantially in 2 years following 2016 CDC guideline for prescribing opioids for chronic pain.

The rate of major thromboembolism within 90 days was 1.2% for placebo and 1.0% for dalteparin.

BUP associated with lower likelihood of any opioid use among participants with mood disorders, without mental disorder, compared to MET.

Reported HRQOL remains consistent in youth with T1D, but multiple comorbidities and mental health conditions linked to decline.

Data show 21.2% of patients with CAD reported angina at least once monthly, with 12.5% reporting daily or weekly angina.

An expert discussion on the recent FDA committee decision to support teplizumab in delaying clinical type 1 diabetes.

Potential public health benefit of OAT linked to 50% lower risk of all-cause mortality.

Data show 1 in 5 surgical patients who receive prescriptions for benzodiazepine go on to use them persistently.